Answers are grounded in this paper and cite their sources.
The Cilostazol Albumin Treatment in Subarachnoid Hemorrhage (CATS) trial evaluates eight active cilostazol-human albumin regimens and a concurrent control in patients with aneurysmal subarachnoid hemorrhage. This case study examines the proposed adaptive regimen-selection design and the tradeoffs associated with allocation, stopping, and reducing the candidate regimens. The binary endpoint was Common Data Elements-defined delayed cerebral ischemia within 14 days. The selected design combines protected control allocation, response-adaptive allocation, interim stopping, and two-dimensional normal dynamic linear model borrowing. Primary operating characteristics were obtained from 1,000 trials per scenario using Fixed and Adaptive Clinical Trial Simulator version 7.0.0. Reproducible independent-arm simulations used 5,000 trials per scenario (50,000 for recalibrated allocation comparisons) to examine purpose-built comparison strategies and sensitivity to missing outcomes, control risk, burn-in, and omitted regimens. We distinguish the probability of any Go decision from power to identify a truly beneficial treatment. The estimated global-null family-wise type I error rate was 0.104 for the selected design and 0.100 for the fixed benchmark. Under albumin-favored and cilostazol-favored gradients, respectively, Go probability was 0.858 and 0.838 versus 0.610 and 0.600 with fixed equal allocation; every active regimen was beneficial, so Go probability also measures power to identify a beneficial regimen. Expected enrollment was 308.3 and 307.9 versus 400.0. In independent-arm simulations without borrowing, the Statistical Analysis Plan allocation rule increased power from 0.697 to 0.777 and from 0.703 to 0.780 relative to fixed allocation under the same Go rule, with both calibrated to a 10% global-null target. Ten percent missing outcomes reduced power from 0.750 to 0.707 in the albumin-favored gradient. Reduced-arm designs could not identify a beneficial monotherapy omitted from the candidate set. For a nine-arm Phase II trial of related regimens with a protected concurrent control, the selected design increased Go probability and reduced expected enrollment relative to fixed equal allocation at a similar global-null family-wise type I error rate. Adaptive allocation added power in independent-arm simulations, whereas removing monotherapy arms could exclude the only beneficial regimen. These comparisons do not establish superiority over standard adaptive design classes or isolate the benefit of model borrowing.
No takes yet. Share an insight, caveat, or question.
Qureshi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: